Trial NCT04412291, EudraCT 2020-001748-24
Publication IMMCOVA - IMMCOVA, Unpublished (2021) (unpublished results)
Funding: Public/non profit (Karolinska University Hospital)
Conflict of interest: *
Methods | |
RCT Blinding: Unblinded | |
Location :
Multicenter / Sweden Follow-up duration (days): 28 | |
Inclusion criteria |
|
Exclusion criteria |
|
Interventions | |
Treatment
Tocilizumab 8 mg/kg (max 800mg) IV single dose |
|
Control
Standard care | |
Participants | |
Randomized participants : Standard care=27 Tocilizumab=22 | |
Characteristics of participants N= 49 Mean age : NR 37 males Severity : Mild: n=0 / Moderate: n=0 / Severe: n=49 Critical: n=0 Number of vaccinated participants: NR | |
Primary outcome | |
In the register Time to recovery [ Time Frame: Day 1 through Day 29 ] | |
In the report NR | |
Documents available |
Protocol NR Statistical plan NR Data-sharing willing stated in the publication: Not reported |
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Low |
General comment | The study is not published yet. Data presented was extracted from study registry and The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group "Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis." JAMA. 2021;326(6):499–518. ).The authors have been contacted in order to obtain the results. |